Cleveland Clinic Joins Interventional Study Using GRAIL’s Multi-Cancer Early Detection Test to Help Guide Clinical Care
Cancer detection company GRAIL has announced that Cleveland Clinic has joined GRAIL’s PATHFINDER Study, a prospective, multi-cancer clinical study that is evaluating the implementation of Galleri™, an investigational multi-cancer early detection blood test, into clinical practice for the first time. Today, most cancers are found too late, when outcomes are often fatal, because most deadly cancers have no available screening tests. Current recommended screenings are critical, but they only cover four cancers and screen for a single cancer at a time. In fact, cancers responsible for...